Results 61 to 70 of about 20,818 (203)

Diltiazem added blood cardioplegia and myocardial protection [PDF]

open access: yes, 2000
Amaç: Bu çalıışmanın amacı Ca++ antagonisti olan diltiazemin kardiyoplejik solüsyona eklenmesinin myokard korunmasındaki etkilerinin araıştırılmasıdır. Yöntem: Aortakoroner bypass operasyonu uygulanan 30 elektif hasta, kontrol ve çalıışma grubu olarak ...
Dişçigil, Berent   +10 more
core  

The Impact of a Visualized Steerable Sheath on Radiofrequency Catheter Ablation for First‐Time Atrial Fibrillation Ablation: A Prospective, Randomized, Single‐Blind Study

open access: yesCatheterization and Cardiovascular Interventions, Volume 108, Issue 3, Page 924-934, September 1, 2026.
ABSTRACT Background A 3D electroanatomical mapping (3D‐EAM) visualized steerable sheath was designed to improve catheter placement and reduce radiation exposure during ablation, an established treatment for atrial fibrillation (AF). However, prospective randomized data comparing the procedural and clinical outcomes of visualized and non‐visualized ...
Chun‐Kai Chen   +4 more
wiley   +1 more source

Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients with Severe Preeclampsia: A Randomized, Single-Blind, Controlled Trial

open access: yesInternational Journal of Hypertension, 2020
Background. Postpartum preeclampsia is a serious disease related to high blood pressure that occurs commonly within the first six days after delivery. Objective.
Gilberto Arias-Hernández   +3 more
doaj   +1 more source

Suzetrigine Is Not Expected to Have Clinically Relevant DDIs with Apixaban and Rivaroxaban Based on PBPK Modeling

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Suzetrigine (VX‐548) is a first‐in‐class, oral, non‐opioid, FDA‐approved analgesic for the treatment of moderate to severe acute pain. Based on Phase 1 clinical drug–drug interaction (DDI) studies, suzetrigine is a weak‐to‐moderate cytochrome P450 3A (CYP3A) inducer and thus has the potential to decrease exposure and impact efficacy of CYP3A ...
Guanyu Wang   +5 more
wiley   +1 more source

Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and Proarrhythmic Effects

open access: yesArquivos Brasileiros de Cardiologia, 2014
Background: Pazopanib (PZP) may induce prolonged cardiac repolarization and proarrhythmic effects, similarly to other tyrosine kinase inhibitors.
Tulay Akman   +3 more
doaj   +1 more source

Prognostic Value of Spatial Trajectory of J‐Point Amplitude Across Left Precordial Leads in a Community‐Based Population

open access: yesAnnals of Noninvasive Electrocardiology, Volume 31, Issue 5, September 2026.
In NHANES III adults, latent class trajectory analysis identified a J‐point phenotype characterized by higher V4 amplitude and a steep decline toward V6. This spatial trajectory was independently associated with increased long‐term all‐cause mortality and cardiac death, suggesting prognostic value beyond conventional early repolarization criteria ...
Chenhui Tai, Zhe Wang
wiley   +1 more source

Pharmacokinetics of diltiazem hydrochloride delay-onset sustained-release pellet capsules in healthy volunteers

open access: yesBrazilian Journal of Pharmaceutical Sciences, 2013
The pharmacokinetics (PK) of ordinary tablets and sustained release capsules of diltiazem hydrochloride in human clinical trials had been studied. The PK of diltiazem hydrochloride delay-onset sustained-release pellet capsules, a new dosage form, has not
Xi-Qing Yan   +7 more
doaj  

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

open access: yesActa Ophthalmologica, Volume 104, Issue 6, Page e630-e647, September 2026.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen   +3 more
wiley   +1 more source

A SHAP‐Informed Formal Feature Attribution Framework for Drug–Drug Interaction Risk in Large‐Scale Claims Data

open access: yesClinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Pairwise drug–drug interaction databases flag co‐prescribed pairs, but they under‐weight multi‐drug combinations that drive adverse drug events in older adults. We studied that gap in Virginia All‐Payer Claims Database records (2016–2019) for adults aged 65–114 years with non‐opioid emergency department visits (n = 1182 cases; 16,105 matched ...
R. Jerome Dixon, Elvin T. Price
wiley   +1 more source

An Observational Study of the Effect of Concomitant Levetiracetam on Apixaban Concentrations in a Hospital Cohort

open access: yesClinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Despite the lack of evidence of a mechanism‐based drug interaction, some professional organizations have advised caution coadministering apixaban and levetiracetam. Eligible patients taking apixaban with or without levetiracetam for any indication for at least 72 h were screened from the electronic medical records.
Chazmyn Riley   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy